The Groundbreaking HBV RNA Biomarker Discovery

Researchers from Hiroshima University have unveiled a pivotal advancement in managing chronic hepatitis B (CHB), identifying serum hepatitis B virus (HBV) RNA as a superior biomarker for predicting hepatocellular carcinoma (HCC) risk even after viral suppression through nucleos(t)ide analogue (NA) therapy. This finding addresses a critical gap in post-treatment surveillance, where patients achieve undetectable HBV DNA but remain vulnerable to liver cancer due to persistent viral elements like covalently closed circular DNA (cccDNA).

In a retrospective cohort study involving 311 NA-treated CHB patients, primarily with HBV genotype C prevalent in Japan, those with quantifiable HBV RNA levels faced a 3.2-fold higher HCC risk, independent of conventional factors such as age, gender, and liver function scores. This positions Hiroshima University's Graduate School of Biomedical and Health Sciences at the forefront of hepatology innovation, enhancing precision medicine for HBV patients worldwide.

Chronic Hepatitis B: A Persistent Global and Japanese Challenge

Chronic hepatitis B, caused by the HBV—a DNA virus that integrates into host hepatocytes—progresses to cirrhosis and HCC in 15-40% of untreated cases. Globally, it impacts 296 million people, but in Japan, prevalence hovers around 0.6%, equating to roughly 700,000-1 million carriers despite robust vaccination programs since 1986 for infants and universal coverage from 2016.

Japan's HCC burden, once dominated by hepatitis C virus (HCV), now sees HBV contributing to about 15% of the 20,000 annual cases, with incidence declining due to antiviral therapies and screening. Yet, NA drugs like entecavir suppress replication (undetectable HBV DNA) in over 95% of patients but rarely achieve functional cure (HBsAg loss), leaving cccDNA as a reservoir for oncogenesis.

NA Therapy: Suppression Without Eradication

Nucleos(t)ide analogues revolutionized CHB management by inhibiting HBV polymerase, achieving viral suppression in most patients within months. The step-by-step process involves: (1) baseline assessment of HBV DNA, HBsAg, and ALT; (2) initiating NA; (3) monitoring for undetectable HBV DNA (<20 IU/mL); (4) long-term maintenance to prevent flares.

However, despite suppression, 10-year HCC risk remains 2-5% annually in cirrhotics, dropping to 0.5-2% in non-cirrhotics—necessitating lifelong ultrasound and AFP surveillance per Japanese Society of Hepatology guidelines. Hiroshima's study highlights why: transcriptional activity from cccDNA persists, measurable via serum HBV RNA (pregenomic RNA, pgRNA).

Unpacking HBV RNA: From Transcription to Biomarker

HBV RNA in serum reflects pgRNA export from infected hepatocytes, bypassing intracellular degradation, thus indicating cccDNA activity and potential for viral rebound or carcinogenesis. Unlike HBV DNA (replication marker), RNA signals active transcription; HBcrAg reflects core protein from cccDNA/integrants.

In the Hiroshima-led research, HBV RNA was quantified via sensitive assays (cutoff ≥10 copies/mL) on stored sera at suppression time. This non-invasive metric outperforms imaging for early risk stratification.

Methodology of the Hiroshima-Ogaki Collaborative Study

Conducted at Ogaki Municipal Hospital (2000-2024), the study enrolled 311 patients (88.5% genotype C) post-NA suppression. Key steps:

• Retrospective review of records for demographics, ALT, HBsAg, fibrosis scores.
• Assayed stored sera for HBV RNA and HBcrAg.
• Follow-up median 11 years; HCC via imaging/biopsy.
• Statistical analysis: Kaplan-Meier, Cox regression (adjusted HRs).

31 HCC cases emerged, validating the cohort's real-world relevance.

Photo by Vini Brasil on Unsplash

Striking Results: 17.8% 15-Year HCC Incidence in HBV RNA Positive

Patients with detectable HBV RNA showed 17.8% 15-year cumulative HCC incidence vs. 8.8% in negatives (p=0.026). Multivariate analysis confirmed aHR 3.313 (95% CI 1.154-9.507). Subgroup synergy: HBV RNA+ and ALBI grade ≥-2.60 (liver dysfunction) yielded 15.8% 5-year risk.

HBV RNA Outperforms HBcrAg and Traditional Markers

HBcrAg (≥2.1 log U/mL) failed significance (aHR 0.821), underscoring HBV RNA's edge. Compared to PAGE-B score (age, gender, platelets), RNA adds independent prognostic value.

• Benefits: Simple blood test, reflects cccDNA dynamics.
• Risks: Assay sensitivity/cost, genotype specificity.
• Comparisons: Superior AUC for HCC prediction vs. HBcrAg.

Lead author Takashi Kumada notes: "HBV RNA's predictive power surprised us, given HBV's DNA nature."

Clinical Implications: Tailored Surveillance Strategies

This biomarker enables risk-stratified care: high-risk (HBV RNA+) get 3-6 month ultrasounds/AFP; low-risk biennial. In Japan, with aging CHB cohort (median age 50s), it optimizes resource use amid declining prevalence.

Stakeholders: JSH may update guidelines; patients gain personalized reassurance. Real-world case: A 55-year-old genotype C carrier, suppressed 10 years, HBV RNA+ prompted early HCC detection via intensified scans.

Hiroshima University's Hepatology Excellence

Hiroshima's Hepatology lab, under Prof. Masataka Tsuge, excels in HBV elimination strategies, gene analyses, and trials. Collaborators Junko Tanaka (epidemiology) and Tomoyuki Akita drive multicenter efforts. The Graduate School fosters interdisciplinary talent, with outputs like HBV RNA predictors advancing global standards.

Prospective researchers: Explore research assistant jobs or Japanese university opportunities at AcademicJobs.com.

Japan's HBV Landscape and Research Momentum

Post-vaccination, Japan's HBV carriers age, shifting HCC to non-cirrhotic cases. National screening catches 70% early, but biomarkers like HBV RNA refine this. Multi-perspective: Government funds via AMED; pharma (Roche supported study) invests; patients advocate via JLIA.

Timeline: 1986 infant vax → 2016 universal → 2026 projected carriers <500k.

Photo by Bruna Santos on Unsplash

Future Outlook: Multicenter Validation and Therapies

Kumada calls for multicenter trials across genotypes. Emerging: RNAi silencing cccDNA, immune modulators for functional cure (HBsAg loss <1%). Actionable: Discuss HBV RNA testing with hepatologists; join trials via clinical research jobs.

Hiroshima's work promises reduced HCC mortality, positioning Japanese higher ed as viral hepatitis leaders. For career advice, visit higher ed career advice.